A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical TumorsShow others and affiliations
2021 (English)In: Biology, E-ISSN 2079-7737, Vol. 10, no 7, article id 580
Article in journal (Refereed) Published
Abstract [en]
Pheochromocytomas/Paragangliomas (PPGLs) and adrenocortical tumors are rare neoplasms with significant heterogeneity in their biologic and clinical behavior. Current diagnostic and predictive biomarkers include hormone secretion, as well as histopathological and genetic features. PPGL diagnosis is based on biochemical measurement of catecholamines/metanephrines, while histopathological scoring systems have been proposed to predict the risk of malignancy. Adrenocortical tumors are mostly benign, but some can be malignant. Currently, the stage of disease at diagnosis and tumor grade, appear to be the most powerful prognostic factors. However, recent genomic and proteomic studies have identified new genetic and circulating biomarkers, including genes, immunohistochemical markers and micro-RNAs that display high specificity and sensitivity as diagnostic or prognostic tools. In addition, new molecular classifications have been proposed that divide adrenal tumors in distinct subgroups with different clinical outcomes.
Place, publisher, year, edition, pages
MDPI, 2021. Vol. 10, no 7, article id 580
Keywords [en]
Ki-67, chromogranin A, genetic, metanephrines, micro-RNA, molecular
National Category
Medical Genetics and Genomics
Identifiers
URN: urn:nbn:se:oru:diva-93448DOI: 10.3390/biology10070580ISI: 000678182600001PubMedID: 34201922Scopus ID: 2-s2.0-85109147704OAI: oai:DiVA.org:oru-93448DiVA, id: diva2:1584550
2021-08-122021-08-122025-02-10Bibliographically approved